Gene therapy in human breast cancer

Turkish Journal of Medical Sciences

Volumn 32, Issue 4, 2002, Pages 283-291

  Abaan, Ogan D ^a   Criss, Wayne E ^b  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Gene therapy; Vector targeting; Viral vectors

Indexed keywords

BREAST CANCER;

ONCOLOGY; PATIENT TREATMENT;

GENES;

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; BETA INTERFERON; DOXORUBICIN; ETOPOSIDE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; ONCOLYTIC VIRUS; ONYX 015; PACLITAXEL; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; RIBOZYME; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TUMOR NECROSIS FACTOR;

BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; REVIEW; SUICIDE GENE; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM;

EID: 0036069662     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. The future of human gene therapy
2. Viral vectors for gene therapy
3. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics
4. Gene delivery with synthetic (non-viral) carriers
5. Key issues in non-viral gene delivery
6. Safety testing for replication-competent retrovirus associated with gibbon ape leukemia virus-pseudotyped retroviral vectors
7. High-capacity 'gutless' adenoviral vectors
8. Chimeric viral vectors - The best of both worlds?
9. Adeno-associated virus for gene therapy
10. Adeno-associated virus vectors for gene therapy: More pros than cons?
11. Gene delivery and gene therapy with herpes simplex virus-based vectors
12. Gene transfer technology in therapy: Current applications and future goals
13. Gene therapy: The first decade
14. Gene therapy. Therapeutic approaches and implications
15. Novel applications of liposomes
16. Developing nonviral DNA delivery systems for cancer and infectious disease
17. Suicide genes: Past, present, and future perspectives
18. Bystander effect in Herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication
19. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-florocytosine of human colorectal cancer xenografts
20. The role of cellular- and prodrug-associated factors in the bystander effect induced by the Varicella zoster and Herpes simplex viral thymidine kinases in suicide gene therapy
21. The molecular biology of cancer
22. Tp53 gene therapy: A key to modulating resistance to anticancer therapies?
23. Comparison of tumor suppressor p53, p21, and p16 gene therapy effects on glioblastoma tumorigenicity in situ
24. KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity
25. An Adenovirus expressing mutant p27 showed more potent antitumor effects than adenovirus-p27 wild type
26. Targeting tumor angiogenesis with gene therapy
27. Cytokine gene therapy: Hopes and pitfalls
28. Cancer and the immune system
29. Oncolytic viruses and cancer therapy
30. Delivery systems intended for in vivo gene therapy of cancer: Targeting and replication competent viral vectors
31. Oncogenes, repressor genes and viruses
32. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
33. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55 kD gene deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial
34. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy
35. Ribozyme gene therapy: Applications for molecular medicine
36. Peptide nucleic acids: Versatile tools for gene therapy strategies
37. Virosomes: Evolution of the liposome as a targeted drug delivery system
38. Pharmacological aspects of targeting cancer gene therapy to endothelial cells
39. Gene therapy designer promoters for tumour targeting
40. Conditional gene targeting for cancer gene therapy
41. Viral vector targeting
42. Startegies for targeting therapeutic gene delivery
43. Retargeting gene delivery using surface engineered retroviral vector particles
44. Ligand directed retroviral targeting of human breast cancer cells
45. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells
46. Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer
47. Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach
48. Eradication of breast cancer xenografts by hyperthermic suicide gene therapy under the control of the heat shock protein promoter
49. Evaluation of a new dual-specific promoter for selective induction of apoptosis in breast cancer cells
50. Potential of Varicella zoster virus thymidine kinase as a suicide gene in breast cancer cells
51. Inducible expression of herpes simplex virus thymidine kinase increases sensitivity to ganciclovir but does not enhance bystander effect in breast cancer cells
52. Self-deleting suicide vectors (SDSV): Selective killing of p53-deficient cancer cells
53. Radiosensitivity of human breast cancer cells transduced with wild-type p53 gene is influenced by the p53 status of parental cells
54. Tumor suppression and therapy sensitization of localized and metastatic breast cancer by adenoviral p53
55. Adenoviral-mediated gene therapy with Ad 5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines
56. Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21
57. INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells
58. INK4A gene transfer significantly suppresses human breast cancer growth
59. KiP1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells
60. KiP1: A strategy for breast cancer gene therapy
61. The p53-independent tumoricidal activity of an adenoviral vector encoding a p27-p16 fusion tumor suppressor gene
62. Construction and characterization of recombinant adenoviruses expressing human BRCA1 or murine Brca1 genes
63. Progress in antiangiogenic gene therapy
64. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice
65. AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice
66. Stimulation of mammary tumorigenesis by systemic application of matrix metalloproteinase 4 gene delivery
67. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNRα
68. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: Results of a phase 1 clinical trial
69. Anti-tumor immunity induced by interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells
70. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity
71. Strategies for cancer gene therapy using adenoviral vectors
72. Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells
73. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy
74. Transfer of p14ARF gene in drug-resistant human breast cancer MCF-7/Adr cells inhibits proliferation and reduces doxorubicin resistance
75. Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model
76. Cancer vaccines